SAVA Stock Price, Cassava Sciences Inc Quote, Chart

Market Summary

USD21.13+0.39

Delayedas of 25 Apr 2024, 11:10 am

1.88%

SAVA Stock Price

View Fullscreen

SAVA RSI Chart

SAVA Valuation

Market Cap

896.5M

Price/Earnings (Trailing)

-9.22

Price/Sales (Trailing)

341.35

Price/Free Cashflow

-10.87

MarketCap/EBT

-67.02

SAVA Price/Sales (Trailing)

SAVA Profitability

EBT Margin

-509.36%

Return on Equity

-70.72%

Return on Assets

-64.1%

Free Cashflow Yield

-9.2%

SAVA Fundamentals

SAVA Revenue

Revenue (TTM)

2.8M

SAVA Earnings

Earnings (TTM)

-97.2M

Earnings Growth (Yr)

-9.33%

Earnings Growth (Qtr)

18.45%

Breaking Down SAVA Revenue

52 Week Range

16.4028.65

(Low)(High)

Last 7 days

-2.5%

Last 30 days

5.3%

Last 90 days

-15.6%

Trailing 12 Months

-5.3%

How does SAVA drawdown profile look like?

SAVA Financial Health

Current Ratio

9.13

SAVA Investor Care

Shares Dilution (1Y)

5.25%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	73.0K	374.0K	1.2M	2.8M
2021	47.0K	33.0K	41.0K	49.0K
2020	308.0K	241.0K	166.0K	112.0K
2019	190.5K	275.5K	340.5K	328.0K
2018	24.0K	27.0K	38.0K	105.5K
2017	94.0K	71.0K	54.0K	38.0K
2016	79.0K	95.0K	103.0K	107.0K
2015	45.0K	47.0K	51.0K	57.0K
2014	30.9M	20.6M	10.3M	47.0K
2013	9.9M	9.1M	8.3M	41.1M
2012	11.2M	11.2M	11.2M	10.9M
2011	16.8M	16.9M	16.7M	11.5M
2010	0	19.3M	18.1M	16.8M
2009	0	0	0	20.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Cassava Sciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 18, 2024	kupiec james william	acquired	33,000	22.00	1,500	chief medical officer
Apr 17, 2024	schoen eric	acquired	33,000	22.00	1,500	chief financial officer
Aug 23, 2023	robertson sanford	bought	523,500	17.45	30,000	-
Aug 22, 2023	barry richard	bought	275,907	16.65	16,571	-
Aug 21, 2023	barry richard	bought	32,020	16.8	1,906	-
Jun 12, 2023	scannon patrick j md phd	acquired	950	0.95	1,000	-
May 24, 2023	barbier remi	sold (taxes)	-241,011	25.25	-9,545	president and ceo
May 24, 2023	barbier remi	sold (taxes)	-1,205,010	25.25	-47,723	president and ceo
May 24, 2023	barbier remi	acquired	240,988	16.87	14,285	president and ceo
May 24, 2023	barbier remi	acquired	1,204,990	16.87	71,428	president and ceo

Which funds bought or sold SAVA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	Venturi Wealth Management, LLC	unchanged	-	-1,110	10,145	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-76.4	-99,000	27,000	-%
Apr 23, 2024	FIFTH THIRD BANCORP	unchanged	-	-31,346	286,495	-%
Apr 22, 2024	Raymond James Financial Services Advisors, Inc.	sold off	-100	-226,586	-	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	new	-	116,404	116,404	-%
Apr 22, 2024	Byrne Asset Management LLC	added	8.06	-1,959	73,450	0.05%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	added	2.63	-124,929	1,542,990	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	119,877	459,699	-%
Apr 22, 2024	PFG Investments, LLC	new	-	443,945	443,945	0.03%
Apr 19, 2024	Cutler Group LLC / CA	reduced	-62.83	-471,000	237,000	0.08%

Are Funds Buying or Selling SAVA?

Are funds buying SAVA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SAVA

No. of Funds

Unveiling Cassava Sciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	5.51%	2,324,626	SC 13G/A
Feb 01, 2024	barbier remi	5.7%	2,488,531	SC 13G/A
Jan 26, 2024	blackrock inc.	7.2%	3,037,415	SC 13G/A
Feb 09, 2023	vanguard group inc	5.27%	2,196,925	SC 13G/A
Feb 08, 2023	cassava sciences inc	-	2	SC 13G/A
Feb 01, 2023	blackrock inc.	6.1%	2,564,528	SC 13G/A
Feb 09, 2022	vanguard group inc	5.15%	2,060,819	SC 13G
Feb 03, 2022	barbier remi	5.%	20	SC 13G/A
Feb 03, 2022	blackrock inc.	6.9%	2,760,978	SC 13G/A
Feb 16, 2021	cvi investments, inc.	0%	0	SC 13G/A

Recent SEC filings of Cassava Sciences Inc

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	4	Insider Trading
Apr 17, 2024	4	Insider Trading
Apr 15, 2024	8-K	Current Report
Mar 26, 2024	DEF 14A	DEF 14A
Mar 22, 2024	ARS	ARS
Feb 28, 2024	8-K	Current Report
Feb 28, 2024	10-K	Annual Report
Feb 13, 2024	SC 13G/A	Major Ownership Report
Feb 07, 2024	8-K	Current Report
Feb 01, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Cassava Sciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	-1.39%	-19.31%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.44%	-28.86%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	5.41%	-4.57%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.99%	-29.65%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-10.10%	-42.90%	-11.39	15.18	425.83%	18.94%
BBIO	4.4B	-	-14.83%	70.74%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-7.99%	-0.08%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.49%	-30.64%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-7.01%	-17.50%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.67%	-6.03%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-13.72%	-45.61%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	-0.25%	294.45%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-18.06%	3.25%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	70.91%	57.98%	-0.24	2.14	-13.45%	66.37%

Cassava Sciences Inc News

Latest updates

Cassava Sciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4
Revenue	77.0%	1,554,000	878,000	314,000	31,000	14,000	15,000	13,000	7,000	6,000	7,000	27,000	72,000	60,000	82,000	94,000	92,000	72,500	17,000	9,000	7,000	5,000
Operating Expenses	-1.9%	20,937,000	21,345,000	19,917,000	17,821,000	14,444,000	9,753,000	5,138,000	3,533,000	2,624,000	1,437,000	1,163,000	1,222,000	1,576,000	779,000	1,153,000	1,451,000	750,000	1,284,000	2,461,000	2,167,000	-
S&GA Expenses	16.5%	3,285,000	2,819,000	2,969,000	2,915,000	4,102,000	1,712,000	1,237,000	1,004,000	1,105,000	1,038,000	818,000	778,000	838,000	831,000	845,000	877,000	748,000	848,000	998,000	1,099,000	-
R&D Expenses	-4.7%	17,652,000	18,526,000	-	-	-	-	-	-	-	-	-	-	-	-	308,000	574,000	-511,500	1,463,000	1,463,000	1,068,000	1,544,500
EBITDA Margin	-	-	-	-	-	-	-324	-403	-283	-118	-80.07	-55.10	-43.09	-40.45	-38.90	-49.48	-72.44	-126	-441	-	-	-
EBT Margin	24.6%	-5.09	-6.75	-10.01	-19.35	-288	-345	-428	-300	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	5.5%	-19,134,000	-20,257,000	-19,328,000	-17,527,000	-14,172,000	-9,562,000	-5,125,000	-3,526,000	-2,618,000	-1,430,000	-1,136,000	-1,150,000	-1,516,000	-697,000	-1,059,000	-1,359,000	-677,500	-1,267,000	-2,452,000	-2,160,000	-
Net Income Margin	19.3%	-27.46	-34.03	-42.88	-63.46	-660	-508	-384	-185	-	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	7.6%	-20,985,000	-22,706,000	-12,580,000	-23,955,000	-8,087,000	-36,805,000	-5,139,000	-2,306,000	-1,175,000	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-12.1%	152	173	197	218	235	207	227	244	267	274	281	284	94.00	25.00	25.00	26.00	23.00	18.00	19.00	20.00	20.00
Current Assets	-13.7%	130	150	175	195	211	183	204	222	244	252	280	284	94.00	25.00	25.00	26.00	23.00	18.00	19.00	19.00	20.00
Cash Equivalents	-14.9%	121	142	168	187	201	175	197	210	233	242	278	282	94.00	24.00	25.00	26.00	23.00	18.00	19.00	19.00	20.00
Net PPE	-1.0%	22.00	22.00	22.00	23.00	23.00	23.00	22.00	21.00	21.00	21.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-18.5%	14.00	17.00	18.00	14.00	7.00	9.00	9.00	7.00	13.00	7.00	5.00	3.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Current Liabilities	-18.5%	14.00	17.00	18.00	14.00	7.00	8.00	9.00	7.00	13.00	6.00	5.00	3.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Shareholder's Equity	-11.4%	137	155	179	204	228	199	218	237	254	268	276	281	92.00	24.00	24.00	25.00	22.00	17.00	18.00	19.00	20.00
Retained Earnings	-5.8%	-380	-359	-334	-307	-283	-264	-244	-224	-207	-193	-183	-178	-174	-172	-170	-169	-168	-167	-166	-165	-163
Additional Paid-In Capital	0.6%	518	515	514	512	511	463	462	462	461	461	460	460	267	196	195	195	191	184	184	184	184
Shares Outstanding	0.3%	42.00	42.00	42.00	42.00	42.00	40.00	40.00	40.00	39.00	40.00	40.00	40.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	967	-	-	-	1,100	-	-	-	3,200	-	-	-	71.00	-	-	-	19.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	15.9%	-22,316	-26,530	-19,924	-13,255	-21,320	-21,550	-11,114	-23,530	-7,987	-14,764	-5,139	-2,306	-1,175	-2,171	-842	-1,194	-589	-730	-591	-604	-565
Share Based Compensation	124.3%	2,129	949	835	673	616	470	485	495	1,001	24.00	5.00	250	482	4.00	249	9.00	465	1.00	328	342	809
Cashflow From Investing	-86.4%	-41.00	-22.00	6.00	-357	335	-1,156	-1,466	-425	-100	-22,041	-	-	-	-	260	100	-	-	-	-18.00	-
Cashflow From Financing	146.3%	1,143	464	889	64.00	47,338	136	119	211	-	75.00	1,274	190,992	70,607	991	236	3,613	5,866	-	-	-60.00	-72.00

SAVA Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Operating expenses:
Research and development, net of grant reimbursement	$ 89,423	$ 68,032	$ 24,813
General and administrative	16,534	11,988	8,055
Total operating expenses	105,957	80,020	32,868
Operating loss	(105,957)	(80,020)	(32,868)
Interest income	7,833	2,777	49
Other income, net	907	997	434
Net loss	$ (97,217)	$ (76,246)	$ (32,385)
Net loss per share, basic and diluted (in dollars per share)	$ (2.32)	$ (1.9)	$ (0.82)
Shares used in computing net loss per share, basic and diluted (in shares)	41,932	40,202	39,405

SAVA Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 121,136	$ 201,015
Prepaid expenses and other current assets	8,497	10,211
Total current assets	129,633	211,226
Operating lease right-of-use assets	0	122
Property and equipment, net	21,854	22,864
Intangible assets, net	176	622
Total assets	151,663	234,834
Current liabilities:
Accounts payable and other accrued expenses	10,573	4,017
Accrued development expense	3,037	2,280
Accrued compensation and benefits	200	170
Operating lease liabilities, current	0	104
Other current liabilities	385	492
Total current liabilities	14,195	7,063
Operating lease liabilities, non-current	0	35
Other non-current liabilities	0	197
Total liabilities	14,195	7,295
Commitments and contingencies (Notes 10, 11 and 12)
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding	0	0
Common stock, $0.001 par value; 120,000,000 shares authorized; 42,236,919 and 41,735,557 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	42	42
Additional paid-in capital	518,195	511,049
Retained Earnings (Accumulated Deficit)	(380,769)	(283,552)
Total stockholders' equity	137,468	227,539
Total liabilities and stockholders' equity	$ 151,663	$ 234,834

About Cassava Sciences Inc

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.

CEO	Mr. Remi Barbier
WEBSITE	cassavasciences.com
INDUSTRY	Biotechnology
EMPLOYEES	26

Cassava Sciences Inc Frequently Asked Questions

What is the ticker symbol for Cassava Sciences Inc? What does SAVA stand for in stocks?

SAVA is the stock ticker symbol of Cassava Sciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cassava Sciences Inc (SAVA)?

As of Wed Apr 24 2024, market cap of Cassava Sciences Inc is 896.49 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SAVA stock?

You can check SAVA's fair value in chart for subscribers.

What is the fair value of SAVA stock?

You can check SAVA's fair value in chart for subscribers. The fair value of Cassava Sciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cassava Sciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SAVA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cassava Sciences Inc a good stock to buy?

The fair value guage provides a quick view whether SAVA is over valued or under valued. Whether Cassava Sciences Inc is cheap or expensive depends on the assumptions which impact Cassava Sciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SAVA.

What is Cassava Sciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, SAVA's PE ratio (Price to Earnings) is -9.22 and Price to Sales (PS) ratio is 341.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SAVA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Cassava Sciences Inc's stock?

In the past 10 years, Cassava Sciences Inc has provided -0.063 (multiply by 100 for percentage) rate of return.